March 1, 2012
- Vol. 366 No. 9
-
Audio Summary
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
C. Harrison and Others
Patients with myelofibrosis who were treated with ruxolitinib, a JAK1 and JAK2 inhibitor, showed significant responses with respect to spleen size and quality of life. No effect on overall survival was seen, but one third of the patients assigned to the best available therapy could not be evaluated.787-798 - A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
S. Verstovsek and Others
This trial showed clinically significant responses in spleen size and quality of life among patients with myelofibrosis receiving ruxolitinib, a JAK1 and JAK2 inhibitor. The agent has some myelotoxicity, but this study showed a survival advantage with ruxolitinib.799-807 - A Randomized Trial of Nicotine-Replacement Therapy Patches in Pregnancy
T. Coleman and Others
In this placebo-controlled trial, the addition of a nicotine patch to behavioral support for smoking cessation did not significantly increase rates of prolonged abstinence lasting until delivery, nor did it affect rates of adverse pregnancy and birth outcomes. Compliance rates were low.808-818 - Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury
J.T. Giacino and Others
In this placebo-controlled trial of patients in a vegetative or minimally conscious state, amantadine accelerated functional recovery. Recovery slowed after amantadine was discontinued, and functional outcomes at 6 weeks were similar in the amantadine and placebo groups.819-826
- Intensive Therapy and GFR in Type 1 Diabetes
To the Editor: The Diabetes Control and Complications Trial (DCCT) and the observational study that followed it, the Epidemiology of Diabetes Interventions and Complications (EDIC) (Dec. 22 issue),1 provide strong evidence that the risk of an impaired ...856-858 - Emergency Hospitalizations for Adverse Drug Events
To the Editor: We commend Budnitz and colleagues (Nov. 24 issue)1 for their contribution to our understanding of emergency hospitalizations caused by adverse drug events. However, as a result of detection bias, it is likely that the relative contribution ...858-860 - Primary Hyperparathyroidism
To the Editor: In their Clinical Practice article on primary hyperparathyroidism, Marcocci and Cetani (Dec. 22 issue)1 do not discuss ethanol ablation. In early 2000, investigators reported that ethanol ablation might have a role in some patients who ...860-861 - Ulcerative Colitis
To the Editor: In their recent review article, Danese and Fiocchi (Nov. 3 issue)1 do not emphasize the importance of thromboembolic disease as a complication of ulcerative colitis. Patients with ulcerative colitis are at increased risk for thromboembolic ...861-863 - More on Acutely Injured Patients Receiving Dabigatran
To the Editor: Although we agree with Cotton and colleagues (Nov. 24 issue)1 that specific antidotes for the new oral anticoagulants are desirable, we disagree with some of the other statements in their letter to the Editor. Although it is true that ...863-864 - Bleeding Risk with Dabigatran in the Frail Elderly
In an audit of patients who had bleeding events during treatment with dabigatran, common factors included advanced age, impaired renal function, low body weight, and prescriber error.864-866 - Vemurafenib Sensitivity Skin Reaction after Ipilimumab
Patients with melanoma who have received ipilimumab appear to be at an increased risk for a drug-hypersensitivity rash when treated with vemurafenib.866-868